EIF6 (eukaryotic translation initiation factor 6) is a multifunctional regulator of ribosomal function and protein synthesis. Mechanistically, EIF6 binds to 60S ribosomal subunits and prevents their premature association with 40S subunits, thereby blocking unproductive 80S formation and regulating translation initiation 1. In the nucleus, EIF6 associates with pre-60S subunits and facilitates their maturation and export; cytoplasmic release requires RACK1-dependent protein kinase C activity 1. EIF6 plays a critical role in ribosome biogenesis and acts as a stimulatory factor for insulin/growth factor-dependent translation 1. Beyond translation, EIF6 participates in miRNA-mediated gene silencing and regulates wound healing by suppressing keratin 6B expression 2. Clinically, EIF6 dysregulation is implicated in multiple diseases. EIF6 overexpression occurs in specific human tumors, with evidence from lymphoma models showing that EIF6 depletion improves survival 1. In Shwachman-Diamond syndrome (SDS), a ribosomopathy caused by SBDS mutations, EIF6 accumulation on 60S subunits contributes to pathology; somatic EIF6 inactivation provides genetic rescue and antileukemic effects 34. In colorectal cancer, network analysis identified EIF6 as a critical therapeutic target 5. These findings position EIF6 as a key therapeutic node in cancer and inherited ribosomopathies.